BioPorto Diagnostics A/S looks for FDA approval for its kidney diagnostic test
BioPorto Diagnostics A/S (CPH:BIOPOR) CEO Peter Eriksen joins Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.
The Copenhagen, Denmark based in-vitro diagnostics company provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Its product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury.